PDS Biotechnology Corp filed a Form 4 on November 17, 2026, disclosing that its Chief Scientific Officer was granted an employee stock option to purchase 299,567 shares of common stock on November 16, 2026, subject to stockholder approval of the company's 2026 Equity Incentive Plan.
Key Highlights
- Reporting person: PDS Biotechnology Corp, identified as Chief Scientific Officer of the issuer
- Option grant date: November 16, 2026
- Shares subject to option: 299,567 shares of common stock
- Exercise price: $0.9241 per share
- Expiration date: November 16, 2036
- Stockholder approval required: The option is not exercisable until stockholder approval of the 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c) is obtained
- Vesting schedule: Equal monthly installments over four years beginning December 16, 2026, contingent upon stockholder approval and continued service
PDS Biotechnology CSO Option Grant Contingent on 2026 Equity Plan Approval
According to the Form 4 filed with the SEC on November 17, 2026, PDS Biotechnology Corp (NASDAQ:PDSB), in its capacity as a reporting person and identified as Chief Scientific Officer of the issuer, received a grant of an employee stock option to purchase 299,567 shares of common stock at an exercise price of $0.9241. The transaction code reported is "A" (acquired), and the price of the derivative security is listed as $0.00. The option was granted on November 16, 2026, and is set to expire on November 16, 2036.
The filing states that the option "was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c)." The filing further discloses that "the option is not exercisable until stockholder approval has been obtained." Contingent upon that approval, the shares are to vest in equal monthly installments over four years, beginning December 16, 2026, subject to the reporting person's continued service through each vesting date.
The filing also notes a cancellation provision: "In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation." Following the reported transaction, the number of derivative securities beneficially owned is listed as 299,567, held directly. The form was signed by Spencer Brown, Attorney-in-Fact, on November 17, 2026.
What Was Disclosed
A Form 4 filed November 17, 2026, disclosed the grant of a stock option covering 299,567 shares at $0.9241 to PDS Biotechnology's Chief Scientific Officer on November 16, 2026, contingent on stockholder approval of the company's 2026 Equity Incentive Plan.




Please wait processing your request...